Daily Respiratory Research Analysis
Analyzed 180 papers and selected 3 impactful papers.
Summary
Practice-changing guidance from ERS/ESGE/ESTS recommends endobronchial and oesophageal endosonography as the first-line approach for mediastinal staging in lung cancer, favoring combined EBUS/EUS over mediastinoscopy. Translational advances include an orally efficacious broad-spectrum paramyxovirus polymerase inhibitor with strong efficacy in ferret and cotton rat models, and a mechanistic study implicating inflammation-driven mitochondrial ROS dysfunction in the early initiation of pulmonary fibrosis after sepsis.
Research Themes
- Minimally invasive endosonographic diagnosis and staging in lung cancer
- Broad-spectrum antiviral therapeutics for respiratory paramyxoviruses
- Mitochondrial ROS dysregulation driving early fibrotic remodeling after inflammation/sepsis
Selected Articles
1. ERS/ESGE/ESTS clinical practice guidelines on endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer.
This multi-society, GRADE-based guideline recommends endobronchial and oesophageal endosonography over mediastinoscopy for mediastinal staging, with combined EBUS‑TBNA + EUS(‑B)‑FNA as the minimal standard. It discourages routine add‑on mediastinoscopy after negative endosonography, endorses endosonography for re‑staging, standardizes 21/22‑G needles, and confirms high suitability for PD‑L1 testing.
Impact: These recommendations will immediately influence diagnostic pathways worldwide, reducing invasive surgery while maintaining staging accuracy. Harmonized training and procedural standards can improve quality and equity of lung cancer care.
Clinical Implications: Adopt combined EBUS/EUS as first-line mediastinal staging and re-staging; avoid routine add-on mediastinoscopy after negative endosonography; use 21/22‑G needles; rely on EBUS‑TBNA specimens for PD‑L1; build competence via simulation and validated assessments.
Key Findings
- Endosonography is recommended over mediastinoscopy for mediastinal nodal staging in suspected NSCLC.
- Systematic multistation sampling and combined EBUS‑TBNA + EUS(‑B)‑FNA are preferred over EBUS alone.
- Routine add‑on mediastinoscopy after negative endosonography is not recommended; endosonography is suggested for re‑staging after induction therapy.
- 21G/22G TBNA needles are standard; insufficient evidence to support routine use of alternative needle types or cryobiopsy.
- EBUS‑TBNA samples are highly suitable for PD‑L1 testing.
Methodological Strengths
- Systematic literature review with GRADE methodology across 12 predefined clinical questions
- Multi‑society consensus (ERS/ESGE/ESTS) ensuring broad disciplinary expertise and applicability
Limitations
- Evidence gaps for specific device choices (e.g., alternative needle types, cryobiopsy)
- Heterogeneity in operator expertise and health‑system resources may affect implementation
Future Directions: Prospective comparative studies on needle types and cryobiopsy; implementation research on training pathways and quality metrics; prospective validation of PD‑L1 adequacy across centers.
BACKGROUND: In lung cancer, adequate treatment selection relies on accurate diagnosis and staging. Tissue sampling is generally indicated. This guideline explores the role of endosonography METHODS: Task force members were selected from ERS (European Respiratory Society), ESGE (European Society of Gastrointestinal Endoscopy), and ESTS (European Society of Thoracic Surgeons). Twelve guideline questions were formulated. Systematic literature searches were performed in MEDLINE and Embase (final searches: Apr-2025). GRADE methodology was applied for assessing the certainty of evidence and developing recommendations. RESULTS: In (suspected) non-small cell lung cancer (NSCLC), endosonography is recommended over mediastinoscopy for mediastinal nodal tissue staging. Systematic staging is suggested over targeted staging as the minimal standard. Ideally, combined EBUS-TBNA+EUS(-B)-FNA is performed instead of EBUS-TBNA alone. Add-on mediastinoscopy after a negative endosonography is not recommended. Endosonography is suggested over mediastinoscopy for re-staging after induction therapy. EBUS-TBNA and EUS(-B)-FNA are recommended for centrally located tumours adjacent to the major airways/oesophagus. Both EUS-B-FNA and EUS-FNA are suggested for left adrenal gland analysis. It is suggested that competence is acquired in a simulation-based environment and ensured using valid assessment methods. 21G/22G TBNA needles are considered the standard; there is insufficient evidence to support the structural use of alternative needle sizes/types or cryobiopsy. EBUS-TBNA has high suitability rate for PD-L1 assessment. CONCLUSIONS: Endobronchial and oesophageal endosonography provide accurate and minimally invasive tests for the diagnosis and staging of lung cancer.
2. Developmental candidate GHP-88310/EIDD-3608 with high tolerability and oral efficacy in measles and respiratory paramyxovirus models.
GHP‑88310 (EIDD‑3608) is a next‑generation, orally active broad‑spectrum inhibitor of orthoparamyxovirus polymerases with improved tolerability in ferrets and dogs. It reduced HPIV3 loads in cotton rats, achieved complete survival and reduced viremia/viral shedding in ferret CDV infection, and showed sterilizing activity against HPIV3 in human airway organoids.
Impact: This candidate offers a rare, orally deliverable, broad‑spectrum option against clinically important respiratory paramyxoviruses with strong preclinical efficacy and tolerability.
Clinical Implications: If translated to humans, an oral pan‑paramyxovirus polymerase inhibitor could transform outpatient management of HPIV infections and measles‑like disease, particularly for high‑risk or immunocompromised patients; supports rapid advancement to early‑phase clinical trials.
Key Findings
- GHP‑88310 demonstrated broad antiviral activity (HPIV3, SeV, MeV, CDV) with improved tolerability in ferrets and dogs; 2000 mg/kg/day was well tolerated in 7‑day studies.
- In HPIV3‑infected cotton rats, oral GHP‑88310 lowered respiratory tract viral burden; in CDV‑infected ferrets it produced complete survival, reduced viremia and shedding, and mitigated lymphocytopenia.
- Human airway epithelium organoids showed sterilizing activity against HPIV3 at physiological concentrations; once‑daily dosing was efficacious across models.
Methodological Strengths
- Cross‑species validation (cotton rat, ferret, dog) plus human airway organoid model
- Pharmacokinetic and tolerability profiling supporting dose selection and translation
Limitations
- Preclinical evidence; human safety and efficacy remain to be established
- Resistance barrier and real‑world coverage across paramyxovirus diversity not yet defined
Future Directions: Advance to phase 1/2 trials with virologic endpoints; assess resistance selection pressure; explore prophylactic/post‑exposure indications and combination strategies.
Orthoparamyxoviruses, such as human parainfluenza virus type 3 (HPIV3) and measles virus (MeV), are a major health threat. We discovered an orally efficacious broad-spectrum inhibitor of orthoparamyxovirus polymerases. However, here, we found that tolerability in higher mammals was limited. We report the development of the clinical candidate analog GHP-88310 (EIDD-3608), which combines improved oral efficacy with favorable tolerability in nonrodents (ferrets and dogs). GHP-88310 was active against HPIV3, Sendai virus (SeV), MeV, and related canine distemper virus (CDV). In 7-day tolerability studies, daily doses of 2000 mg/kg were well tolerated. Pharmacokinetic analysis revealed altered plasma exposure of GHP-88310 compared to the original hit. In HPIV3-infected cotton rats, GHP-88310 lowered the respiratory tract viral load. Dosing of ferrets infected with CDV, causing lethal measles-like disease, resulted in complete survival, reduction of viremia and shed viral load, and alleviated lymphocytopenia. Once-daily GHP-88310 was efficacious in the CDV-ferret and HPIV3-cotton rat models. The compound was sterilizing against HPIV3 at physiological concentrations in human airway epithelium organoids.
3. Inflammation-driven mitochondrial dysfunction and ROS accumulation orchestrate pulmonary fibrotic remodeling in sepsis.
Integrating multi‑omics with animal models, the authors show that septic lungs undergo pronounced mitochondrial dysfunction and ROS activation, initiating fibrotic signaling in the acute phase. Six ROS‑regulatory mitochondrial genes correlate with sepsis outcomes, TNF‑α/IL‑1β drive persistent ROS, and ROS overload reprograms fibroblasts; single‑cell data map disrupted immune–parenchymal crosstalk.
Impact: Provides a mechanistic framework linking inflammatory cytokines, mitochondrial ROS dysregulation, and early fibroblast reprogramming—highlighting actionable nodes for preventing post‑sepsis fibrotic lung remodeling.
Clinical Implications: Supports exploration of mitochondrial/ROS‑targeted therapies and cytokine modulation (e.g., TNF‑α/IL‑1β axes) in early sepsis to mitigate long‑term fibrotic lung remodeling and functional decline.
Key Findings
- During inflammation, lungs show stronger immune amplification and more severe mitochondrial dysfunction than other organs, initiating fibrotic signaling in the acute phase.
- Six mitochondrial ROS‑regulatory genes (Bcl2l1, Gsr, Msrb3, AA467197, Stom, Sod2) correlate with clinical outcomes in sepsis.
- TNF‑α/IL‑1β are persistently overexpressed in septic lungs and act as critical drivers of ROS activation; ROS overload induces fibroblast damage and functional reprogramming.
- Bulk and single‑cell transcriptomics reveal altered immune–parenchymal cell communication underlying pro‑fibrotic remodeling.
Methodological Strengths
- Integrated multi‑omics with in vivo cytokine perturbations and in vitro validation of fibroblast reprogramming
- Single‑cell and bulk transcriptomics to map intercellular signaling changes
Limitations
- Predominantly preclinical; translation to human interventional targets requires validation
- Abstract truncation limits detail on specific cell subsets and ligand–receptor pairs
Future Directions: Validate mitochondrial/ROS and cytokine targets in human sepsis cohorts; test early‑intervention strategies to prevent post‑sepsis fibrotic remodeling; develop biomarkers from the six‑gene ROS signature.
Inflammation-induced pulmonary fibrosis is an irreversible and severe complication that leads to persistent decline in lung function and increased mortality; however, its early pathogenesis is still unclear. This study aimed to systematically elucidate the initiation mechanism of pulmonary fibrosis in the early stages of inflammation. By integrating multi-omics data and animal models, we found that lung exhibits stronger immune amplification and more severe mitochondrial dysfunction in comparison with other organs during inflammation, consequently fibrotic signaling is initiated in the acute phase. Mitochondria-related gene analysis identified six key genes (Bcl2l1, Gsr, Msrb3, AA467197, Stom, and Sod2) involved in the regulation of reactive oxygen species (ROS) metabolism, which were closely associated with clinical outcomes in sepsis. Temporal data and TNF-α/IL-1β intervention experiments revealed that these cytokines are persistently overexpressed in septic lungs, serving as critical drivers of ROS activation. In vitro assays further confirmed that ROS overload directly induces cellular damage and functional reprogramming of fibroblasts. Through bulk and single-cell transcriptomic analyses, we elucidated the alteration of intercellular communication between immune and parenchymal cells, and identified Col13a1